


VENTURE STUDIO OF ALLOY THERAPEUTICS

82% S

Over the next decade, tremendous value will
be created in medicine.




Over the next decade,
tremendous value will be
created in medicine.

- ✓ Founded in **2021** within Alloy Therapeutics.
- ✓ Building **9 companies** pursuing 19 therapeutic programs.
- ✓ A new **venture studio model** enabling scalable value creation.
- ✓ Focused on a world-class network of **entrepreneur scientists**.
- ✓ Raising a **\$25M fund** to invest early.

82\rs

VENTURE STUDIO OF ALLOY THERAPEUTICS



WHY BIOTECH & WHY NOW?

**We're capitalizing on new
opportunities by deploying
capital, science, and talent.**


We build early-stage drug companies

We're capitalizing on this opportunity by deploying **capital**, **science**, and **talent**.

1

CAPITAL OPPORTUNITY

More capital and value available



2

VALIDATED SCIENCE

New classes of therapies from 2011-2022

40%

of new drug approvals target new biological mechanisms.

134%

increase in biologic approvals in the last decade.

3

UNMATCHED TALENT

We partner with company builders



Scientist entrepreneurs

Venture & enablement team

Alloy platform


82YS

A new era for biotech

Capital outpacing opportunities.

Capital opportunity ¹

Increasing Fund



A new era for biotech

Emergence of new classes of therapies over the last decade.

2
**Validated
science**

Emergence of new classes of therapies over the last decade

40%


of new drug approvals target
new biological mechanisms

On average from
2017-2021

134%

increase in biologic approvals in
the last decade

110 from 2011-2021
vs. 47 from 2000-2010





A new era for biotech

An exceptionally talented team and unmatched partners.

Unmatched talent

3





WHAT WE DO

**82VS maximizes access,
efficiency, and expertise for
asymmetric value creation.**

THE VENTURE STUDIO MODEL

Full stack company creation.

Model	Statement	Resources	Business Ideas	Builds Team	Finds Capital	Co-Founder	Support Services	Scale-Up Methods
Venture Studio	"We have capital, an idea, and all the tools to develop it. Let's find the right talent to work on this ideas as a co-founder."	↑ Capital ↑ Support	●	●	●	●	●	●
VC	"This startup has promise and we think it will 10x. Let's put some money into it, and exit in a few years."	↑ Capital ↓ Support			○		○	
Accelerator	"Let's take an existing startup, accept it into our program, and offer them the tools to grow."	↓ Capital ↑ Support			○		○	○
Incubator	"Let's brainstorm topics that we find interesting and hopefully invest in some of the ideas that develop from it."	↓ Capital ↓ Support	○		○		○	○

How can we do this?

- 1 We are the first **interdependent venture studio** embedded within a **drug discovery services organization**.

Our strategic advantage is the ability to utilize all of Alloy's scientific tools, platforms, and expertise to generate drug assets and data early in the company creation process.

- 2 We build the most **capital efficient multi-asset drug companies**.

82VS builds companies that are unburdened by the cost of maintaining the underlying drug discovery platforms. Alloy pays for and continues to evolve drug discovery technologies and enabling services so we can build lean companies that only utilize what we need.

- 3 We include **collaborators**, including **VCs**, at every step of the way – even the **Seed stage**.

We are a valuable partner to traditional biotech VCs looking to do more company creation. We invite them to invest in the Pre-Seed and Seed rounds with us on the same terms, without doing the NewCo build.

THE VENTURE STUDIO MODEL

Relentless drive towards value creation through making medicine.

Model	Statement	Resources	Business Ideas	Builds Team	Finds Capital	Co-Founder	Support Services	Scale-Up Methods
Venture Studio	"We have capital, an idea, and all the tools to develop it. Let's find the right talent to work on this ideas as a co-founder."	↑ Capital ↑ Support	●	●	●	●	●	●
VC	"This startup has promise and we think it will 10x. Let's put some money into it, and exit in a few years."	↑ Capital ↓ Support			○		○	
Accelerator	"Let's take an existing startup, accept it into our program, and offer them the tools to grow."	↓ Capital ↑ Support			○		○	○
Incubator	"Let's brainstorm topics that we find interesting and hopefully invest in some of the ideas that develop from it."	↓ Capital ↓ Support	○		○		○	○

How can we do this?

1 Discover

We are a venture studio leveraging Alloy's pre-competitive drug discovery platforms. Established drug discovery, scientific, and lab resources allow entrepreneurs to start their first experiment on day one.

2 Partner

We partner with academics, entrepreneurs, target-rich companies, pharma, and VC. We lead with our drug discovery work, helping others advance targets of interest.

3 Build

We build asset-focused companies while continuing to incorporate new modalities and drug discovery platforms accessible throughout the Alloy ecosystem. Alloy creates new platforms and services on demand to support individual new companies if needed.


4 Industrialize

We industrialize repeatable company launch processes across legal, HR, finance, operations, and marketing to minimize startup time and allow scientists to focus on the science.

82VS & ALLOY THERAPEUTICS

Value creation through an integrated 82VS and Alloy ecosystem

2022	Portfolio	9	19	4	
		COMPANIES	PROGRAMS	DISEASE AREAS	
2023	Projection	15	32	8	4
		COMPANIES	PROGRAMS	DISEASE AREAS	EXITS





Free access to Alloy's platforms.

- 1 Alloy democratizes access to foundational, pre-competitive biologics discovery technologies and services.
- 2 Alloy offers our technologies and capabilities to the entire drug discovery community—from academic scientists, small and medium biotech, to the largest biopharma—on affordable, non-exclusive terms.
- 3 Alloy develops, improves, licenses, and shares foundational, pre-competitive drug discovery platform technologies.

130+

PARTNERS

16
of 50TOP PHARMA
PARTNERS

5

RESEARCH
SITES

Boston, MA
Athens, GA
San Francisco, CA
Basel, CH
Cambridge, UK

82VS INCLUDED ACCESS



ANTIBODIES



TCR MIMICS & TCR



GENETIC MEDICINES



CELL THERAPY



CONJUGATES




PEPTIDES



DELIVERY

HOW WE'RE DIFFERENT

The 82VS ecosystem




82VS IS DIFFERENT

Capital, science, and incentives aligned to execute

Model	Example	Access to Capital	Access to Technology	Access to Discovery	Scalable	Enables Entrepreneur	Speed of Execution
Our Model	82VS						
Incubator + Fund	curie.bio						
Incubator	LabCentral						
Holding Company	bridgebio						
VC Fund	FOUNDERS FUND						
Venture Creation	Flagship Pioneering						
Corporate VC	Pfizer Ventures						

82VS scales like a \$1B fund with the return potential of seed stage vehicles – the best of both worlds.



NO COLLABORATOR LEFT UNTURNED

Strong networks across the entire ecosystem.

Venture capitalist, biotechs, experienced drug developers, and academic/nonprofit researchers all become apart of the 82VS team of builders - an unparalleled network of collaborators.

Experienced Drug Developers



sanofi

RESILIENCE

COMPASS THERAPEUTICS

Company Builders

PRAxis

volastra

carisma THERAPEUTICS

entrada THERAPEUTICS

Sage Therapeutics

NIDO BIOSCIENCES

Photys

Guide THERAPEUTICS

seqWell

amagm THERAPEUTICS

82VS

Vcs and Biotechs

PYXIS ONCOLOGY

CHAMPIONS ONCOLOGY

polarispartners

THIRD ROCK VENTURES

5AM VENTURES

ma2e

Academia & Nonprofits

Mass General Brigham

THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH

Memorial Sloan Kettering Cancer Center

Cleveland Clinic


MARBLE CENTER FOR CANCER NANOMEDICINE

American Cancer Society

82VS DILIGENCE

Deep, standardized diligence for fast cycles

FAST PILOTS is our due diligence framework that enables our team to quickly and comprehensively assess and explore new opportunities. Throughout the entire ideation and company formation process, we track and iterate on FAST PILOTS to drive towards high-value company concepts with detailed scientific, financial, and operational alignment and strategy.



82VS CASE STUDY

24 months from formation to Series A fundraising

COMPANY PROFILE




● Aakha
○ Biologics

Hemanta Baruah, PhD, CEO of Aakha Biologics

Track Record: 20+ years of antibody discovery. Led Sintilimab (anti-PD-1), Anti-CD38 (Phase I), Anti OX40 (Phase I) discovery, DF4001 and DF5008 to IND enabling studies (licensed by BMS), 30+ patents in antibody discovery development.

ADIMAB



82VS PORTFOLIO COMPANIES

Exceptional entrepreneurs and scientists are building with 82VS.



 **Broadwing Bio**

Andrew Peterson, PhD

CEO, Broadwing Bio

Track Record: Led multiple Ab-based drug discovery projects through phase 2 studies. Led genetic engineering and sequencing teams at Genentech. Led an international consortium developing genomic tools for genetic discovery and target ID.

Genentech UCSF Health



 **aldebaran therapeutics**

Carlos Loya, PhD

CEO, Aldebaran Therapeutics

Track Record: Founding team of SAGE Therapeutics (SAGE) and Praxis Precision Medicines (PRAX). Managed and co-led teams that raised over \$350M in private and public financing. Contributed to the advancement of 7 new drugs to clinical development and 1 FDA-approved product (Zulresso).

PRAXIS   



Ypsilon
THERAPEUTICS

Dongxing Zha, PhD

Board member, Ypsilon

Track Record: Led the ORBIT platform at MD Anderson Cancer Center, a Moon Shots platform focused on biologic and cell-based therapies, where he oversaw the team that advanced the first TCR mimic antibody and an agonistic anti-OX40 mAb to the clinic for the treatment of various cancers.



"Working with company builders at 82VS and leveraging Alloy discovery streamlines the process of building a novel TCR therapeutics company. It takes less than one year from company idea to identification of clinical candidates."

"82VS Venture Studio is an ideal ecosystem that supports entrepreneurs to rapidly build multi-asset companies with world-class drug discovery platforms and operational expertise."

"Working with a world-class Ab discovery team allied with a set of experienced and innovative entrepreneurs and investment professionals provided me with a uniquely powerful opportunity to bring my ideas to life."

82VS PORTFOLIO COMPANIES

Exceptional entrepreneurs and scientists are building with 82VS.


●● Aakha ○○ Biologics



Hemanta Baruah, PhD

CEO, Aakha Biologics

Track Record: 20+ years of antibody discovery. Led Sintilimab (anti-PD-1), Anti-CD38 (Phase I), Anti OX40 (Phase I) discovery, DF4001 and DF5008 to IND enabling studies (licensed by BMS), 30+ patents in antibody discovery and development.



Message:

82VS offers the perfect opportunity to scientist-turned entrepreneurs to build world-class biotech companies. I was able to focus on science from the first week while 82VS provided me with everything else: funding, discovery, HR, legal and finance.

aldebarkan therapeutics



Carlos Loya, PhD

CEO, Aldebaran Therapeutics

Track Record: Founding team of SAGE Therapeutics (SAGE) and Praxis Precision Medicines (PRAX). Managed and co-led teams that raised over \$350M in private and public financing. Contributed to the advancement of 7 new drugs to clinical development and 1 FDA-approved product (Zulresso).



Message:

"82VS Venture Studio is an ideal ecosystem that supports entrepreneurs to rapidly build multi-asset companies with world-class drug discovery platforms and operational expertise."


◎ Broadwing Bio



Andrew Peterson, PhD

CEO, Broadwing Bio

Track Record: Led multiple Ab-based drug discovery projects through phase 2 studies. Led genetic engineering and sequencing teams at Genentech. Led an international consortium developing genomic tools for genetic discovery and target ID.



Message:

"Working with a world-class Ab discovery team allied with a set of experienced and innovative entrepreneurs and investment professionals provided me with a uniquely powerful opportunity to bring my ideas to life."

Ypsilon THERAPEUTICS



Dongxing Zha, PhD

Board member, Ypsilon

Track Record: Led the ORBIT platform at MD Anderson Cancer Center, a Moon Shots platform focused on biologic and cell-based therapies, where he oversaw the team that advanced the first TCR mimic antibody and an agonistic anti-OX40 mAb to the clinic for the treatment of various cancers.



Message:

"Working with company builders at 82VS and leveraging Alloy discovery streamlines the process of building a novel TCR therapeutics company. It takes less than one year from company idea to identification of clinical candidates."

82VS TEAM & TEAM EXTENSION

Swiss-army-knife infrastructure for building biotech companies.



Trier Bryant
President



Chris Pacheco, PhD
Executive Partner



Iva Toudjarska, MBA, PhD
Venture Partner



Ross Leimberg, PhD
Venture Partner



Lauren Mifflin, MBA, PhD
Venture Partner



Fat Sathirapongsasuti, PhD
Director, Bioinformatics



Melissa Lokugamage, PhD
Venture Associate



Sophia Lai, PhD
Venture Associate



Josh Peters, PhD
Venture Associate



Andrei Ramirez-Valdez, PhD
Venture Associate



Laurel Handler-Vosen
People



Ahmed Anna
Operations



Damon Banks
Legal



Luvuan Fan Mendhi
Finance



Brendan Robertson
Finance



Paul Benedict
IT























Erin Glabets
Marketing & PR



Scott Sun
Lab Operations

82VS PORTFOLIO

9 companies diversified across indications and modalities

Therapeutic Areas	Ideating	Building	Pre-Seed	Raising Seed	Raising Series A
Ocular				   	
Neurology				 	
Oncology	 In process	   	   	 	
Autoimmune		 			
Women's Health	 In process				



ANTIBODIES



TCR MIMICS & TCR



GENETIC MEDICINES

Notes:
¹ JV with Maze Therapeutics; ² JV with Pyxis Oncology


FUND TEAM

A unique intersection of expertise in building both innovative biotech companies and teams for scale and operational excellence.



Errik Anderson

CEO, Alloy Therapeutics



Founded pioneering antibody platform company and multiple therapeutics companies leveraging those insights. **Deep conviction in the importance of enabling the best scientific breakthroughs to advance with minimal restrictions.**



Trier Bryant


President, 82VS



Seasoned people executive who scaled teams and operations for category leaders in finance, consumer tech, and space. **Understands the best companies are dependent on the successful cultivation of talent and operations at scale.**

FUND OVERVIEW

**Structured,
early investing
into great teams.**



FUND OVERVIEW

Key Investment Terms

Fund Size	\$25M
Economics	2% management fee, 20% carry
Investment size	\$1-2M
Number of investments	8-10 companies
Capital deployment	18-24 month
GP commitment	TBD
Strategic ROI	TBD
Social ROI	TBD

Investing Structure

1

\$1M SAFE, \$5M cap
or
\$2M SAFE, \$8M cap

4

Board seat and
pro-rata rights

2

\$2M deferred
payments for Alloy
platform and
discovery services

5


Conversion to
preferred equity at
next priced equity
round or out-
licensing event

3

Integrated
operational and
research support
through Alloy

6

SAFE-1 (and SAFE-2)
preferred equity
converts to pari
passu with Series A



82VS TEAM STATS

A diverse track record across biotech.

Venture

49

DEALS COMPLETED

Business Development

40

DEALS COMPLETED

Science

201

PUBLICATIONS

Building

28

COMPANIES

People

508

EMPLOYEES HIRED

\$1.4B

INVESTED

\$2.3B

VALUE

35

PATENTS

118

DRUG CANDIDATES

394

SHOES OWNED

Opportunity & Purpose

Efficient capital at the right time.


Unique Advantage

Unmatched biotech and team *ecosystem*.

The 82VS Results

Industrialized company and asset creation.

Invest now.



Let's make new medicines, together.

We are grateful for your commitment in partnering with us to advance transformative therapeutics that save lives.


We are a 'science first, people always' organization that is committed to treating everyone in our ecosystem well as we pursue this ambitious mission together.

We pledge to be good stewards of your capital in this journey, working to deliver industry-leading returns while remaining focused on our mission to help patients and their loved ones.

LEGAL DISCLAIMER

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.



82VS

The 82VS name comes from the atomic number for lead, 82.

To us, lead represents the most boring of metals that can form alloys, frequently used in low-cost solder to bring other metals together. This is because we seek to be behind the scenes and to fade into the background as we let our entrepreneurs and their companies take the credit for their great work.

TBD

The affiliated 82VS funds scale our NewCos alongside other investors

All rounds are syndicated after the first seed round, behind top-tier lead investors



Early-stage drug discovery doesn't have to be so slow and expensive.

82VS starts at Discovery and fundraises with data.

82VS companies don't have to reinvent the platform every time; we just invent the drugs. It's like starting the race halfway to the finish line.

+

TRADITIONAL

+

82VS

